Key Concepts:
- AI automation in life sciences
- Regulatory paperwork and documentation
- Product development lifecycle
- Deterministic AI platform
- Fundraising environment for women's health startups
- ROI of AI in healthcare
- Importance of patient safety
- Empowerment of engineering teams with AI
Collate: Automating Life Sciences Paperwork with AI
Amy Feldman from Forbes interviews Sorbby Sarna, founder and CEO of Collate, an AI-driven startup automating paperwork for life sciences companies. Collate was recently named to Forbes' Next Billion Dollar Startups list, a significant achievement given its launch from stealth mode in January.
Origin and Motivation:
Sorbby Sarna's motivation stemmed from her experience at Y Combinator (YC) as a general partner focused on life sciences and healthcare software. Previously, she founded a company focused on early ovarian cancer detection. Witnessing the power of Large Language Models (LLMs), she recognized their potential to alleviate the burden of regulatory paperwork in the life sciences. Sarna felt compelled to create a solution that addresses the entire product development lifecycle holistically, rather than focusing on specific parts.
Fundraising and Market Reception:
Sarna contrasts her experience fundraising for Collate with her previous company in 2012, which focused on women's health and medical devices. She notes the current environment is much more favorable due to the "hotter space" of AI. However, she emphasizes the importance of customer validation over VC validation, focusing on the "aha moments" and reactions from customers.
AI in Healthcare and Life Sciences:
Sarna expresses strong confidence in AI's potential to revolutionize healthcare, predicting it could accelerate the time to market for medical devices, drugs, and diagnostics by a factor of five (possibly even ten). She envisions AI enabling simultaneous filings in multiple countries and automatic adjustments to paperwork based on new standards.
Deterministic AI Platform:
Collate is building a "deterministic platform" around AI workflows to break down silos between different functions within life sciences companies. This requires patience and a long-term commitment, which Sarna is willing to dedicate the next 10 years of her career to.
Surprises and Unexpected Positives:
Sarna was surprised by the openness and receptiveness of leaders in large companies and startups to AI solutions in life sciences. She attributes this to a growing understanding of the ROI of AI and the recognition that Collate is led by someone with a deep understanding of the life sciences and patient safety.
Advice for Founders:
Sarna encourages aspiring founders to "get in" and take the plunge, emphasizing the fun and rewarding nature of creating new software categories and reimagining customer problems with AI. She highlights the empowerment of engineering teams through AI tools, potentially turning 10x engineers into "100x engineers."
Conclusion:
Sorbby Sarna's Collate is poised to transform the life sciences industry by automating regulatory paperwork and streamlining product development. Her experience as both a founder and investor, combined with her deep understanding of the life sciences, positions her to capitalize on the current AI boom and deliver significant value to customers and ultimately, patients. She is grateful for the opportunity to build and help those who are trying to help patients.
AI summaries can miss context or contain errors. Check important details against the original video.
